Quality of Life Questionnaire-Bronchiectasis: Final psychometric analyses and determination of minimal important difference scores

Thorax

Volumn 70, Issue 1, 2015, Pages 12-20

  Quittner, Alexandra L ^a   O'Donnell, Anne E ^b   Salathe, Matthias A ^c   Lewis, Sandra A ^d   Li, Xiaoming ^d   Montgomery, A Bruce ^e   O'Riordan, Thomas G ^d   Barker, Alan F ^f  

^a UNIVERSITY OF MIAMI   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d GILEAD SCIENCES INC   (United States)

^e Cardeas Pharma   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; PLACEBO; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; BRONCHIECTASIS; CONTENT VALIDITY; CONVERGENT VALIDITY; DISCRIMINANT VALIDITY; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL ASSESSMENT; HEALTH STATUS; HUMAN; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSYCHOMETRY; QUALITY OF LIFE; QUALITY OF LIFE QUESTIONNAIRE BRONCHIECTASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYMPTOM ASSESSMENT; TEST RETEST RELIABILITY; VALIDATION STUDY; VERY ELDERLY; ADOLESCENT; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FOLLOW UP; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PROCEDURES; PSYCHOLOGY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZTREONAM; BRONCHIECTASIS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84919754878     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2014-205918     Document Type: Article

References (31)

1. O'Donnell AE. Bronchiectasis. Chest 2008;134:815-23.
2. Bilton D. Update on non-cystic fibrosis bronchiectasis. Curr Opin Pulm Med 2008;14:595-9.
3. Tsang KW, Bilton D. Clinical challenges in managing bronchiectasis. Respirology 2009;14:637-50.
4. McShane PJ, Naureckas ET, Tino G, et al. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2013;188:647-56.
5. Sidhu MK, Mandal P, Hill AT. Bronchiectasis: an update on current pharmacotherapy and future perspectives. Expert Opin Pharmacother 2014;15:505-25.
6. Barker AF. Bronchiectasis. N Engl J Med 2002;346:1383-93.
7. Smith MP, Hill AT. Evaluating success of therapy for bronchiectasis: what end points to use? Clin Chest Med 2012;33:329-49.
8. Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000;162:481-5.
9. Haworth C, Foweraker J, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014;189:975-82.
10. Quittner AL, Marciel KK, Salathe MA, et al. A preliminary Quality of Life Questionnaire-Bronchiectasis: A patient-reported outcome measure for bronchiectasis. Chest 2014;146:437-48.
11. Olveira C, Olveira G, Espildora F, et al. Validation of a quality of life questionnaire for bronchiectasis: psychometric analyses of the Spanish QOL-B-V3.0. Qual Life Res 2014;23:1279-92.
12. US Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. 2009. http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf
13. Barker AF, O'Donnell AE, Flume PA, et al. Aztreonam for Inhalation Solution (AZLI) in patients with non-CF bronchiectasis: the results from two randomized double-blind placebo-controlled Phase 3 trials. Lancet Respir Med 2014;2:738-49.
14. Wild D, Grove A, Martin M, et al. Principles of good practice for the translation and cultural adaptation process for Patient-Reported Outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation. Value Health 2005;8:94-104.
15. Acquadro C, Jambon B, Ellis D, et al. Language and translation issues. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd edn. Philadelphia: Lippincott-Raven Publishers, 1996:575-85.
16. American Thoracic Society. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-17.
17. Euro Quality of Life-5 Dimensions (EQ-5D). http://www.euroqol.org/about-eq-5d.html
18. Wise RA, Brown CD. Minimal clinically important differences in the six-minute walk test and the incremental shuttle walking test. COPD 2005;2:125-9.
19. Puhan MA, Mador MJ, Held U, et al. Interpretation of treatment changes in 6-minute walk distance in patients with COPD. Eur Respir J 2008;32: 637-43.
20. Quittner AL, Marciel KK, Barker AF. Quality of Life-Bronchiectasis. The measure is available without charge at: http://www.psy.miami.edu/qol-b/
21. Ware J, Brook R, Williams K, et al. Conceptualization and measurement of health for adults in the health insurance study. Model of Health and Methodology. Rand Corporation. 1980;R-1987/1-HEW. http://www.rand.org/pubs/reports/2006/R1987.1.pdf
22. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
23. Guyatt GH, Osoba D, Wu AW, et al. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002;77:371-83.
24. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-15.
25. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999;52:861-73.
26. Bilton D, Henig N, Morrissey B, et al. Addition of inhaled tobramycin to ciprofl oxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006;130:1503-10.
27. Lee AL, Button BM, Ellis S, et al. Clinical determinants of the 6-Minute Walk Test in bronchiectasis. Respir Med 2009;103:780-5.
28. Birring SS, Prudon B, Carr AJ, et al. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax 2003;58:339-43.
29. Guyatt GH, Berman LB, Townsend M, et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987;42:773-8.
30. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation: the Saint George's Respiratory Questionnaire. Am Rev of Respir Dis 1992;145:1321-7.
31. Revicki D, Hays RD, Cella D, et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008;61:102-9.